Bactiguard (BACTI) Q4 2024 earnings summary

Executive summary

• Revenues and EBITDA profitability increased for both Q4 and full year 2024, marking a significant turnaround and three consecutive quarters of positive financial development.

• Strategic shift to a license-focused model, phasing out the BIP portfolio and deepening partnerships, notably with BD.

• Wound Management portfolio delivered stable, profitable growth, with expansion in Asia and regulatory approval in India.

• Cost savings exceeded SEK 25 million annually, with resources reallocated to licensing and wound management.

• Strengthened organization with key hires in R&D and business intelligence, enhancing regulatory, clinical, and commercial capabilities.

Financial highlights

• Full-year 2024 revenues reached SEK 261.9 million, up 17.3% year-over-year; Q4 revenues were SEK 68.3 million, up 11.3%.

• Q4 net sales were SEK 63.1 million (+12.1%); full year net sales totaled SEK 241.7 million (+19.9%).

• Q4 EBITDA was SEK 8.4 million (12% margin); full year EBITDA was SEK 18.0 million (6.9% margin), up from -76.1 million in 2023.

• Net loss narrowed to SEK 29.8 million from SEK 138.4 million in 2023; operating cash flow improved to SEK 25.0 million.

• Year-end cash and equivalents stood at SEK 116.7 million; OpEx for the year was SEK 207.9 million, down 12%.

Outlook and guidance

• Confident in continued growth of the BD partnership and license-focused business model, with regulatory filings ongoing for expanded launches.

• Zimmer Biomet trauma agreement revenues will continue, but revenues from the discontinued orthopedics agreement will not recur in 2025.

• Financial targets for 2028 are under review, with updated guidance expected before the end of Q1 2025.

• Focus remains on cost control, EBITDA profitability, and converting early-stage projects into exclusive agreements.